Comparing Editas Medicine (EDIT) & OptiNose (OPTN)

OptiNose (NASDAQ: OPTN) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Valuation and Earnings

This table compares OptiNose and Editas Medicine’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OptiNose N/A N/A N/A N/A N/A
Editas Medicine $6.05 million 248.07 -$97.18 million ($3.24) -10.37

OptiNose has higher earnings, but lower revenue than Editas Medicine.

Profitability

This table compares OptiNose and Editas Medicine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OptiNose N/A N/A N/A
Editas Medicine -1,127.03% -70.19% -37.08%

Analyst Recommendations

This is a summary of recent ratings for OptiNose and Editas Medicine, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OptiNose 0 0 4 0 3.00
Editas Medicine 0 5 4 0 2.44

OptiNose presently has a consensus target price of $29.00, suggesting a potential upside of 68.60%. Editas Medicine has a consensus target price of $27.00, suggesting a potential downside of 19.62%. Given OptiNose’s stronger consensus rating and higher possible upside, analysts clearly believe OptiNose is more favorable than Editas Medicine.

Insider & Institutional Ownership

65.7% of Editas Medicine shares are owned by institutional investors. 19.4% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

OptiNose beats Editas Medicine on 5 of the 8 factors compared between the two stocks.

OptiNose Company Profile

OptiNose, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other. The Company’s lead product, XHANCE (fluticasone propionate) nasal spray, utilizes breath powered exhalation delivery system (EDS), to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation.

Editas Medicine Company Profile

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply